BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...

Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...

U.S.-listed shares of BioNTech SE ended Monday nearly 3.2% lower, weighed down by a weak full-year revenue projection even as ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

In a report released today, Chris Shibutani from Goldman Sachs maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

Canaccord Genuity analyst William Maughan maintained a Buy rating and increased the price target from $171 to $171.44 on Nov. 27, 2024. This analyst has an accuracy rate of 71%. JP Morgan analyst ...

"We expect 2025 to be a data-rich year with multiple important updates from our priority programs," said Chief Executive Ugur Sahin. BioNTech forecast revenue between 1.7 billion euros and 2.2 billion ...

December 13, 2024 US FDA lifts partial clinical hold on BioNTech cancer drug study BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration ...

Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U ...

Ugur Sahin; Chief Executive Officer, Member of the Management Board; Biontech SE Oezlem Tuereci; Chief Medical Office, Member of the Management Board; Biontech SE Welcome to BioNTech's fourth quarter ...

Welcome to BioNTech's Fourth Quarter and Full-Year 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations. Please go ahead. Thank you.